title: [Plasmablastic lymphoma].
abstract: Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of non-Hodgkin lymphoma that commonly occurs in human immunodeficiency virus (HIV)-positive individuals, and affects oral sites. Occasionally, it has been described in HIV-negative patients and involving non-oral sites. Pathologically, PBL is a high-grade B-cell lymphoma that displays the immunophenotype of a terminally differentiated B-lymphocyte with loss of B-cell markers (CD20) and expression of plasma-cell antigens. Epstein-Barr virus infection and MYC rearrangements are frequently observed. Treatment of PBL is challenging because of the lack of established treatment and poor outcomes, with median survival times shorter than one year. In this review, we discuss the clinical and epidemiologic spectrum of PBL as well as its distinct pathological features. Finally, we summarize the currently available approaches for the treatment of patients with PBL.
authors: Servicio de Hematología, Hospital Universitario de Cabueñes, Gijón, Asturias, España. Electronic address: rubenfalva@gmail.com.
authors: Rubén
authors: R
authors: Fernández-Álvarez
authors: Servicio de Hematología Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors: Juan-Manuel
authors: JM
authors: Sancho
authors: Servicio de Hematología Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Barcelona, España.
authors: Josep-María
authors: JM
authors: Ribera
mesh_terms: D003937:Diagnosis, Differential; D006801:Humans; D000069293:Plasmablastic Lymphoma / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D013030:Spain / Q000453:epidemiology
keywords: Bortezomib; Chemotherapy; Human immunodeficiency virus infection; Infección por el virus de la inmunodeficiencia humana; Linfoma plasmablástico; MYC; Oncogén MYC; Plasmablastic lymphoma; Quimioterapia